Table 2.

Disease characteristics of treatment groups

	Pre-HATn = 40	Pre-op erative chemon = 160	No pre-opertaive Txn = 640
Colorectal metastases	16	142 (89%)	120 (19%)
Hepatocellular carcinoma	14	0	132 (20%)
Neuroendocrine	3	2 (1%)	73 (11%)
Cholangiocarcinoma (intrahepatic)	3	3 (2%)	95 (15%)
Sarcoma	0	1 (1%)	22 (3%)
Breast metastases	1	2 (1%)	20 (3%)
Melanoma metastases	0	1 (1%)	14 (2%)
Ovarian metastases	0	0	18 (3%)
Others	3	9 (6%)	146 (23%)

Pre-HAT, pre-operative hepatic arterial therapy; HCC, hepatocellular carcinoma.